Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Long-Term Efficacy and Safety of Obecabtagene Autoleucel (obe-cel) in Adult Patients (pts) with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia ([R/R B-ALL]; Pooled Analysis from ALLCAR19 and FELIX Phase Ib Studies) or Other B-cell Malignancies (ALLCAR19 Extension Study)

Blood (2023) 142 (Supplement 1): 2114.

https://doi.org/10.1182/blood-2023-180666

Published: 2023

Journal Articles

Efficacy and Toxicity of Donor Lymphocyte Infusions in the Management of Mixed Donor-Recipient Chimerism Following Allogeneic Stem Cell Transplantation for Lymphoid Malignancies:- a Study of the LWP-EBMT

Blood (2018) 132 (Supplement 1): 2070.

https://doi.org/10.1182/blood-2018-99-114072

Published: 2018

Journal Articles

Donor Lymphocyte Infusions for the Treatment of Relapsed Non-Hodgkin Lymphoma Following Allogeneic Stem Cell Transplantation: A LWP-EBMT Study

Blood (2018) 132 (Supplement 1): 707.

https://doi.org/10.1182/blood-2018-99-113906

Published: 2018

Journal Articles

Predictors of Response in Patients Receiving CD34-Selected Stem Cell Infusions without Conditioning to Correct Graft Failure Following Allogeneic Stem Cell Transplantation

Maria del Mar Cuadrado, MBBS, Mark W. Lowdell, BSc, MSc, PhD FRCPath, Stuart Ings, Michael J. Watts, PhD, Richard Szydlo, PhD, Chloe Anthias, MD, J. Alejandro Madrigal, MDPhDDSc,FRCP,FRCPath, Panagiotis Kottaridis, FRCPath,PhDMSc, Ben Carpenter, PhD, Rachael Hough, MD BMBS, FRCP, FRCPath, Karl Peggs, MBBChir, Kirsty Thomson, PhD, Emma Morris, FRCPath, MA, MBBChir, PhD MRCP, Ronjon Chakraverty, BMBS, PhD

Blood (2018) 132 (Supplement 1): 204.

https://doi.org/10.1182/blood-2018-99-115054

Published: 2018

Journal Articles

Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency

Blood (2018) 131 (8): 917–931.

https://doi.org/10.1182/blood-2017-09-807487

Published: 2018

Journal Articles

In the Era of Chemoimmunotherapy, Relapse Post Autologous Stem Cell Transplantation for Follicular Lymphoma Is Associated with Prolonged Overall Survival. an Analysis By the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Blood (2017) 130 (Supplement 1): 3299.

https://doi.org/10.1182/blood.V130.Suppl_1.3299.3299

Published: 2017

Journal Articles

Automated Manufacture of CAR19 Donor Lymphocytes Incorporated into an Escalated Dose DLI Protocol: Preliminary Results from the CARD Study

Blood (2017) 130 (Supplement 1): 1993.

https://doi.org/10.1182/blood.V130.Suppl_1.1993.1993

Published: 2017

Journal Articles

Automated Lentiviral Transduction of T Cells with Cars Using the Clinimacs Prodigy

Ulrike Mock*, PhD, Lauren Nickolay*, PhD, Gordon Weng-Kit Cheung, Hong Zhan, PhD, Karl Peggs, MBBChir, MRCP, FRCPath, Ian CD Johnston, PhD, Andrew Kaiser, PhD, Martin Pule, PhD, Adrian Thrasher, MD PhD, Waseem Qasim, MBBS PhD

Blood (2015) 126 (23): 2043.

https://doi.org/10.1182/blood.V126.23.2043.2043

Published: 2015

Journal Articles

First Clinical Application of Talen Engineered Universal CAR19 T Cells in B-ALL

Waseem Qasim, MBBS PhD, Persis Jal Amrolia, Sujith Samarasinghe, MD PhD, Sara Ghorashian, MD PhD FRCPath, Hong Zhan, PhD, Sian Stafford, PhD, Katie Butler, PhD, Gul Ahsan, Kimberly Gilmour, Stuart Adams, PhD, Danielle Pinner, Robert Chiesa, Steve Chatters, PhD, Sue Swift, PhD, Nicholas Goulden, MD PhD, Karl Peggs, MBBChir, MRCP, FRCPath, Adrian J Thrasher, MD PhD, Paul Veys, Martin Pule, PhD

Blood (2015) 126 (23): 2046.

https://doi.org/10.1182/blood.V126.23.2046.2046

Published: 2015

Journal Articles

Alternative Donors (Umbilical Cord Blood and Haploidentical Donors) for Allogeneic Stem Cell Transplantation in Relapsed / Refractory Hodgkin Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party and the Spanish Group of Stem Cell Transplantation (GETH)

Blood (2015) 126 (23): 4399.

https://doi.org/10.1182/blood.V126.23.4399.4399

Published: 2015

Journal Articles

Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution

Blood (2010) 116 (16): 3080–3088.

https://doi.org/10.1182/blood-2010-05-286856

Published: 2010

Journal Articles

Pre-Transplant PET Status May Not Impact on Survival Following Reduced-Intensity Allogeneic Stem-Cell Transplant for Lymphoma. However, Post-Transplant Surveillance with PET May Be Important for Directing Immunotherapy.

Jonathan R Lambert, MRCP, Jamshed B Bomanji, PhD, Nichola Cooper, MRCP, MRCPath, MD, Daniel P Hart, MRCP, Karl Peggs, Kirsty Thomson, Peter J Ell, FMedSci, Stephen Mackinnon, MD

Blood (2008) 112 (11): 3256.

https://doi.org/10.1182/blood.V112.11.3256.3256

Published: 2008

Journal Articles

Phase I Study of Transfer of CD8 Depleted Donor Leukocytes after Allogeneic Stem Cell Transplantation.

Guillermo Orti, MD, Karl Peggs, MD, Kirsty Thomson, MD, Emma Morris, MD, Mark Lowdell, PhD, Stephen Mackinnon, MD, Ronjon Chakraverty, MD

Blood (2008) 112 (11): 2203.

https://doi.org/10.1182/blood.V112.11.2203.2203

Published: 2008

Journal Articles

Long-Term Follow-Up of Reduced Intensity Transplantation with an Alemtuzumab-Containing Regimen for Aggressive Non-Hodgkins Lymphoma.

Kirsty Thomson, MD, Emma Morris, MD, Adrian Bloor, MD, Gordon Cook, MD, Donald Milligan, MD, Anne Parker, MD, Charles Craddock, MD, Lynny Yung, MD, Ronjon Chakraverty, MD, Karl Peggs, MD, Stephen Mackinnon, MD

Blood (2007) 110 (11): 1661.

https://doi.org/10.1182/blood.V110.11.1661.1661

Published: 2007

Journal Articles

Extended Follow-Up of Reduced Intensity Transplantation with an Alemtuzumab-Containing Regimen for Follicular Lymphoma.

Kirsty Thomson, MD, Emma Morris, MD, Donald Milligan, MD, Ann Hunter, MD, Gordon Cook, MD, Adrian Bloor, MD, Charles Craddock, MD, Lynny Yung, MD, Anne Parker, MD, Ronjon Chakraverty, MD, Karl Peggs, MD, Stephen Mackinnon, MD

Blood (2007) 110 (11): 1666.

https://doi.org/10.1182/blood.V110.11.1666.1666

Published: 2007

Journal Articles

The Effect of In Vivo T-Cell Depletion with Alemtuzumab on Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia.

Julio Delgado, Srinivas Pillai, Reuben Benjamin, Dolores Caballero, Rodrigo Martino, Richard Lovell, Kirsty Thomson, Jose A. Perez-Simon, Anna Sureda, Panos Kottaridis, Jesus San Miguel, Karl Peggs, Jorge Sierra, Donald Milligan, Stephen Mackinnon

Blood (2007) 110 (11): 3014.

https://doi.org/10.1182/blood.V110.11.3014.3014

Published: 2007

Journal Articles

Multi-Center Phase II Study of CAMPATH-1H Dose De-Escalation Prior to Nonmyeloablative HLA-Identical Sibling Transplantation.

Ronjon Chakraverty, MD, Nilusha Manji, BSc, Richard Clark, MD, Charles Crawley, MD, Peter Johnson, MD, Effie Liakopoulou, MD, Judith Marsh, MD, Donald Milligan, MD, Emma Morris, MD, Karl Peggs, MD, Kirsty Thomson, MD, John Snowden, MD, Graham Jackson, MD, Stephen Mackinnon, MD

Blood (2007) 110 (11): 1055.

https://doi.org/10.1182/blood.V110.11.1055.1055

Published: 2007

Journal Articles

De-Escalation of the Alemtuzumab Dose Prior to Nonmyeloablative HLA-Identical Sibling Transplantation: Crucial Role of Timing.

Ronjon Chakraverty, MD, Maria Dimopoulou, MD, Julie Glanville, MD, Kirsty Thomson, MD, Karl Peggs, MD, Donald Milligan, MD, Gordon Cook, MD, Graham Jackson, MD, Anne Parker, MD, Ann Hunter, MD, Nigel Russell, MD, Rachel Pearce, Stephen Mackinnon, MD

Blood (2006) 108 (11): 2901.

https://doi.org/10.1182/blood.V108.11.2901.2901

Published: 2006

Journal Articles

Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT

Blood (2005) 105 (11): 4532–4539.

https://doi.org/10.1182/blood-2004-06-2387

Published: 2005

Journal Articles

Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma

Emma Morris, Kirsty Thomson, Charles Craddock, Prem Mahendra, Donald Milligan, Gordon Cook, Graeme Murray Smith, Anne Parker, Steve Schey, Rajesh Chopra, Christopher Hatton, Jane Tighe, Anne Hunter, Karl Peggs, David Linch, Anthony Goldstone, Stephen Mackinnon

Blood (2004) 104 (13): 3865–3871.

https://doi.org/10.1182/blood-2004-03-1105

Published: 2004

NARROW

Long-Term Efficacy and Safety of Obecabtagene Autoleucel (obe-cel) in Adult Patients (pts) with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia ([R/R B-ALL]; Pooled Analysis from ALLCAR19 and FELIX Phase Ib Studies) or Other B-cell Malignancies (ALLCAR19 Extension Study)

Efficacy and Toxicity of Donor Lymphocyte Infusions in the Management of Mixed Donor-Recipient Chimerism Following Allogeneic Stem Cell Transplantation for Lymphoid Malignancies:- a Study of the LWP-EBMT

Donor Lymphocyte Infusions for the Treatment of Relapsed Non-Hodgkin Lymphoma Following Allogeneic Stem Cell Transplantation: A LWP-EBMT Study

Predictors of Response in Patients Receiving CD34-Selected Stem Cell Infusions without Conditioning to Correct Graft Failure Following Allogeneic Stem Cell Transplantation

Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency

In the Era of Chemoimmunotherapy, Relapse Post Autologous Stem Cell Transplantation for Follicular Lymphoma Is Associated with Prolonged Overall Survival. an Analysis By the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Automated Manufacture of CAR19 Donor Lymphocytes Incorporated into an Escalated Dose DLI Protocol: Preliminary Results from the CARD Study

Automated Lentiviral Transduction of T Cells with Cars Using the Clinimacs Prodigy

First Clinical Application of Talen Engineered Universal CAR19 T Cells in B-ALL

Alternative Donors (Umbilical Cord Blood and Haploidentical Donors) for Allogeneic Stem Cell Transplantation in Relapsed / Refractory Hodgkin Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party and the Spanish Group of Stem Cell Transplantation (GETH)

Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution

Pre-Transplant PET Status May Not Impact on Survival Following Reduced-Intensity Allogeneic Stem-Cell Transplant for Lymphoma. However, Post-Transplant Surveillance with PET May Be Important for Directing Immunotherapy.

Phase I Study of Transfer of CD8 Depleted Donor Leukocytes after Allogeneic Stem Cell Transplantation.

Long-Term Follow-Up of Reduced Intensity Transplantation with an Alemtuzumab-Containing Regimen for Aggressive Non-Hodgkins Lymphoma.

Extended Follow-Up of Reduced Intensity Transplantation with an Alemtuzumab-Containing Regimen for Follicular Lymphoma.

The Effect of In Vivo T-Cell Depletion with Alemtuzumab on Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia.

Multi-Center Phase II Study of CAMPATH-1H Dose De-Escalation Prior to Nonmyeloablative HLA-Identical Sibling Transplantation.

De-Escalation of the Alemtuzumab Dose Prior to Nonmyeloablative HLA-Identical Sibling Transplantation: Crucial Role of Timing.

Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT

Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only